Spironolactone may block the action of mitotane. Avoid concomitant use of mitotane with spironolactone.
Mitotane is a strong CYP3A inducer. Concomitant use of Mitotane may decrease the levels of CYP3A substrates, which may reduce the activity of these substrates.
Avoid concomitant use of Mitotane with other CYP3A substrates, where minimal level changes may lead to serious therapeutic failures. If concomitant use cannot be avoided, modify the dosage of the CYP3A substrate in accordance with the approved product labeling.
Avoid concomitant use of Mitotane with hormonal contraceptives.
Mitotane may induce the metabolism of warfarin, which may reduce its level and its efficacy.
Avoid concomitant use of Mitotane with warfarin. If concomitant use cannot be avoided, monitor INR more frequently and adjust warfarin dose as recommended in accordance with the recommendations in the warfarin Prescribing Information.
from FDA,2024.01
The therapeutic effect of Mitotane is aimed at adrenal cortical carcinoma, hyper···【more】
Release date:2024-08-20Recommended:106
Designed for non-surgical adrenocortical carcinoma, hyperplasia, and tumor-induc···【more】
Release date:2024-08-20Recommended:115
Mitotane was developed to address inoperable adrenal cortical carcinoma, hyperpl···【more】
Release date:2024-08-20Recommended:111